The expression of β-microseminoprotein but not CRISP3 is reduced in ovarian cancer and correlates to survival

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3993-3999

  Henriksen, Rudi ^a   Lundwall, Åke ^a   Udby, Lene ^b   Fernlund, Per ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Rigshospitalet   (Denmark)

Author keywords

Microseminoprotein; CRISP3; Immunohistochemistry; Ovarian cancer; Ovary; Survival

Indexed keywords

BETA MICROSEMINOPROTEIN; CYSTEINE RICH SECRETORY PROTEIN 3; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOPSY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; OVARY; PROSTATIC SECRETORY PROTEINS; SALIVARY PROTEINS AND PEPTIDES; SEMINAL PLASMA PROTEINS;

EID: 84866990034     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K and Workman P: Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian Cancer Action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 108: 652-657, 2008.
3. Wong AS and Leung PC: Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res 33: 3-16, 2007.
4. Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H and Kobayashi H: Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer 19: 992-997, 2009.
5. Abrahamsson PA and Lilja H: Three predominant prostatic proteins. Andrologia 22(Suppl 1): 122-131, 1990.
6. Ulvsback M, Lindstrom C, Weiber H, Abrahamsson PA, Lilja H and Lundwall A: Molecular cloning of a small prostate protein, known as beta- microsemenoprotein, MSMB or beta-inhibin, and demonstration of transcripts in non-genital tissues. Biochem Biophys Res Commun 164: 1310-1315, 1989.
7. Weiber H, Andersson C, Murne A, Rannevik G, Lindstrom C, Lilja H and Fernlund P: Beta- microseminoprotein is not a prostate-specific protein. Its identification in mucous glands and secretions. Am J Pathol 137: 593-603, 1990.
8. Baijal-Gupta M, Clarke MW, Finkelman MA, McLachlin CM and Han VK: Prostatic secretory protein (MSMB) expression in human female reproductive tissues, breast and in endometrial cancer cell lines. J Endocrinol 165: 425-433, 2000.
9. Udby L, Calafat J, Sorensen OE, Borregaard N and Kjeldsen L: Identification of human cysteine-rich secretory protein 3 (CRISP-3) as a matrix protein in a subset of peroxidase-negative granules of neutrophils and in the granules of eosinophils. J Leukoc Biol 72: 462-469, 2002.
10. Udby L, Cowland JB, Johnsen AH, Sorensen OE, Borregaard N and Kjeldsen L: An ELISA for SGP28/CRISP-3, a cysteine-rich secretory protein in human neutrophils, plasma, and exocrine secretions. J Immunol Methods 263: 43-55, 2002.
11. Udby L, Lundwall A, Johnsen AH, Fernlund P, Valtonen-Andre C, Blom AM, Lilja H, Borregaard N, Kjeldsen L and Bjartell A: β-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun 333: 555-561, 2005.
12. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE and Scardino PT: Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 13: 4130-4138, 2007.
13. Henriksen R, Funa K, Wilander E, Bäckström T, Ridderheim M and Öberg K: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53: 4550-4554, 1993.
14. Armitage BG: Statistical Methods in Medical Research. Second Edition. Blackwell Scientific Publications, Oxford, UK, 1987.
15. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
16. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
17. Henriksen R, Strang P, Wilander E, Bäckström T, Tribukait B and Öberg K: p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 53: 301-306, 1994.
18. Henriksen R, Strang P, Backstrom T, Wilander E, Tribukait B and Öberg K: Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res 14: 603-608, 1994.
19. Liu AY, Bradner RC and Vessella RL: Decreased expression of prostatic secretory protein MSMB in prostate cancer. Cancer Lett 74: 91-99, 1993.
20. Zhang PJ, Driscoll DL, Lee HK, Nolan C and Velagapudi SR: Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: a study with monoclonal antibody. Hum Pathol 30: 168-172, 1999.
21. Imasato Y, Xuan JW, Sakai H, Izawa JI, Saito Y, Chin JL and Moussa M: MSMB expression after androgen deprivation therapy: A comparative study with prostate-specific antigen in benign prostate and prostate cancer. J Urol 164: 1819-1824, 2000.
22. Kwong J, Lui K, Chan PS, Ho SM, Wong YC, Xuan JW and Chan FL: Expression study of three secretory proteins (prostatic secretory protein of 94 amino acids, probasin, and seminal vesicle secretion II) in dysplastic and neoplastic rat prostates. Prostate 56: 81-97, 2003.
23. Chan PS, Chan LW, Xuan JW, Chin JL, Choi HL and Chan FL: In situ hybridization study of MSMB (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 41: 99-109, 1999.
24. Asmann YW, Kosari F, Wang K, Cheville JC and Vasmatzis G: Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res 62: 3308-3314, 2002.
25. Tsurusaki T, Koji T, Sakai H, Kanetake H, Nakane PK and Saito Y: Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate 35: 109-116, 1998.
26. Hyakutake H, Sakai H, Yogi Y, Tsuda R, Minami Y, Yushita Y, Kanetake H, Nakazono I and Saito Y: Beta-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma. Prostate 22: 347-355, 1993.
27. Sakai H, Tsurusaki T, Kanda S, Koji T, Xuan JW and Saito Y: Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Prostate 38: 278-284, 1999.
28. Girvan AR, Chang P, van Huizen I, Moussa M, Xuan JW, Stitt L, Chin JL, Yamasaki Y and Izawa JI: Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer. Urology 65: 719-723, 2005.
29. Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M, Daigneault L, Panchal C, Sugar L, Jewett MA and Narod SA: A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high-grade cancers at diagnosis. J Urol 175: 1291-1297, 2006.
30. Garde SV, Basrur VS, Li L, Finkelman MA, Krishan A, Wellham L, Ben-Josef E, Haddad M, Taylor JD, Porter AT and Tang DG: Prostate secretory protein (MSMB) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 38: 118-125, 1999.
31. Shukeir N, Arakelian A, Kadhim S, Garde S and Rabbani SA: Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 63: 2072-2078, 2003.
32. Garde S, Fraser JE, Nematpoor N, Pollex R, Morin C, Forté A, Rabbani S, Panchal C and Gupta MB: Cloning, expression, purification and functional characterization of recombinant human MSMB. Protein Expr Purif 54: 193-203, 2007.
33. Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C and Rabbani SA: A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res 64: 5370-5377, 2004.
34. Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ and Annabi B: A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: Implication in tumor angiogenesis. Int J Cancer 118: 2350-2358, 2006.
35. Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ and Beliveau R: A MSMB-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis 22: 429-439, 2005.
36. Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ and Beliveau R: Inhibition of MMP-9 secretion by the anti-metastatic MSMB-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anticancer Drugs 17: 429-438, 2006.
37. Beke L, Nuytten M, Van Eynde A, Beullens M and Bollen M: The gene encoding the prostatic tumor suppressor MSMB is a target for repression by the polycomb group protein EZH2. Oncogene 26: 4590-4595, 2007.
38. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and Akslen LA: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273, 2006.
39. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ and Sood AK: Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67: 1757-1768, 2007.
40. Chunhua L, Hee Dong H and Lingegowda SM: Regulation of tumor angiogenesis by EZH2. Cancer Cell 18: 185-197, 2010.
41. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N and Rotter V: Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23: 5759-2769, 2004.
42. Kosari F, Asmann YW, Cheville JC and Vasmatzis G: Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 11: 1419-1426, 2002.
43. Bjartell A, Johansson R, Björk T, Gadaleanu V, Lundwall A, Lilja H, Kjeldsen L and Udby L: Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 66: 591-603, 2006.